479 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
of spend and the impact of recent acquisitions.
On a GAAP basis, research and development expenses increased 16% to $2.7 billion and on a non-GAAP … expenses and research and development expenses excluding certain specified items as a percentage of revenues, non-GAAP operating expenses, which
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
the net impact of Acquired IPRD charges and licensing income of ($0.28) in 2023. Acquired IPRD refers to certain in-process research and development
8-K
EX-99.1
23fgm6xdp3
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
8-K
EX-99.1
lmx5pq
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
6xszvv6t2j7
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
beoc3vb8xjt0dv
8 Jan 24
Regulation FD Disclosure
10:29am
8-K
EX-99.2
a2hqtxulqb5drxu
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
p1srkk0c cjk
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
qjkx2pnbc0rrw7h1kev5
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.2
rx6jic
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
3q15cqbm5sqa zl
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
DEFA14A
1wlc5i
10 Apr 23
Additional proxy soliciting materials
5:12pm